Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Press Releases

[Dhaka, Bangladesh and Geneva, Switzerland, 15 October 2014]
Study results support WHO recommendations for safe and effective kala-azar treatments in Bangladesh
Today in Dhaka, Bangladesh, results of a four year-long clinical study to test the safety and efficacy of new combination treatments for kala-azar (visceral leishmaniasis) were presented to the Ministry of Health (MoH) of Bangladesh in the presence of Health Minister, Mr Mohammed Nasim. The treatments tested had been recommended by the World Health Organization in 2010 and form part of the treatment arsenal to support the targets for controlling this parasitic disease that infects up to 300,000 people and kills up to 40,000 people worldwide each year. The disease burden in the Indian sub-continent is particularly high, but is currently declining with efforts exerted within the regional elimination programme.

More

[Gondar, Ethiopia and Geneva, Switzerland – October 6, 2014]
Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients
The international research & development (R&D) consortium, AfriCoLeish, formed by six research organizations from East Africa and Europe, has launched a Phase III clinical study to address the extreme difficulty in treating visceral leishmaniasis (VL) in patients who also are HIV-positive. The study will assess the efficacy and the safety of two treatments: a combination treatment of AmBisome® and miltefosine, and AmBisome® alone. This is the first randomized clinical trial in Africa to confirm the World Health Organization’s recommendation for HIV-VL treatment. Two sites, Gondar and Abdurafi, in northwest Ethiopia, one of the highest burden areas in the world, have begun recruiting patients.
[Deutsch] [Español] [Français] [Português]

More

[Bahir Dar, Ethiopia and Geneva, Switzerland – 1 October 2014] 
Results of Large-Scale Roll Out of Combination Treatment for Kala-Azar in Eastern Africa Points to Urgency to Treat Disease Victims as Outbreak Surges in South Sudan
Today in Bahir Dar, Ethiopia, at the occasion of the Leishmaniasis East Africa Platform meeting, which has gathered some 150 African and international leishmaniasis experts, results of a pharmacovigilance – or large-scale treatment safety and efficacy monitoring – plan, carried out by MSF, DNDi, and national partners in Kenya, Sudan, Uganda, and Ethiopia, were presented to key decision makers in order to boost patient access to treatment of kala-azar with the combination of Sodium Stibogluconate and Paromomycin (SSG&PM) in the region. In this large cohort of patients, treated under normal field conditions, the results confirmed the safety and high rate of efficacy of the combination treatment in the fight against this fatal neglected tropical disease.

More

[Geneva, Switzerland, and Summit, NJ, USA – 24 September 2014] 
Celgene Global Health and DNDi Expand Collaboration to Identify Innovative Therapies to Benefit Patients with Neglected Tropical Diseases
Celgene Global Health (CGH), a division of Celgene Corporation (NASDAQ: CELG), and the Drugs for Neglected Diseases initiative (DNDi) strengthen their collaboration with a four-year Research Collaboration Agreement to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs). Celgene will provide DNDi with new data and resources to accelerate clinical development of new treatments for patients with NTDs.

More

[Mexico City, Mexico – 12 August 2014] 
New Drug Candidate for Chagas Disease Tested in Patients in Bolivia
Phase II Trial Launched to Test Safety and Efficacy of ‘Rediscovered’ Fexinidazole in 140 Adults with Chronic Indeterminate Chagas Disease
The Drugs for Neglected Diseases initiative (DNDi) announced today at the International Congress of Parasitology (ICOPA), the launch of a Phase II drug trial to test fexinidazole, a drug shelved in the 1980s and ‘rediscovered’ by DNDi nearly a decade ago, for Chagas disease patients. The drug is also being tested in patients in Africa for two other parasitic diseases, sleeping sickness and visceral leishmaniasis.
[Español] [Português]

More

[Mexico City, Mexico – 11 August 2014] 
The Global Chagas Disease Coalition stages high-level event to encourage increased access to diagnosis and treatment of patients fighting Chagas disease
Of the 8 million people infected in the world, 1 million are Mexican
At the 2014 International Congress of Parasitology (ICOPA), the Global Chagas Disease Coalition launched the event “Let’s Raise Our Voice” to alert the world that of the 8 million patients infected with Chagas disease, 99% have not been treated. The aim of this event is to promote an alliance among governments, civil society, doctors, researchers, and patients to discuss simple actions that can be taken to boost patient access to diagnosis and treatment.
[Español] [Português]

More

[Geneva, Switzerland – 3 June 2014]
DNDi Welcomes Progress Made at WHA in R&D Financing and Coordination for Developing Country Health Needs
Overall political consensus and initial financial commitments secured during recent World Health Assembly, laying foundations for publicly-led research and development to bridge innovation of and access to essential health tools in developing countries
At the recent 67th World Health Assembly (WHA) in Geneva, a global political consensus by the Member States gave a solid ‘go-ahead’ to advance a process that began over a decade ago to ensure that research and development (R&D) for the priority health needs of developing countries benefits from global public leadership. The process, referred to as the Consultative Expert Working Group (CEWG) process, notably aims at securing sustainable financing and coordination to fundamentally link innovation and access to essential health tools. Initial financial commitments were announced by France, Switzerland, Brazil, and Kenya.

More

[Geneva, Switzerland – 22 May 2014]
DNDi Receives Support from Norwegian Agency for Development Cooperation for its Research & Development on Sleeping Sickness
The Drugs for Neglected Diseases initiative (DNDi) welcomes new public funding from the Norwegian Agency for Development Cooperation (NORAD). This grant of NOK 15 million (EUR 1.85 million), to be disbursed over three years (until 2015), will be dedicated to the development of an oral treatment for sleeping sickness, as well as to strengthen local capacities in the endemic African countries through the Human African Trypanosomiasis (HAT) Platform, a network of key regional actors in clinical research for the disease.

More

[Geneva, Switzerland – 19 May 2014]
Paediatric HIV Treatment Initiative (PHTI) to Spur Innovation and Access to Improve the Lives of Children Living with HIV
UNITAID, DNDi, and the Medicines Patent Pool Gather Global Experts, Health Ministries, and Industry Leaders in Support of the Initiative to Expedite Development and Delivery of New Antiretroviral Formulations
On the eve of the 67th World Health Assembly, Ministers of Health from over fifteen countries including Brazil, Chile, Mauritius, and South Africa; industry and global public health leaders; as well as senior representatives from the HIV/AIDS community joined UNITAID Chair Philippe Douste-Blazy at a special event last evening to urge a more coordinated response to caring for the 3.3 million children currently living with HIV. While significant progress has been made over the past 15 years in improving access to antiretroviral treatment for adults, only a quarter of children in need receive ARV therapy today. Each day, 500 children die of HIV/AIDS-related causes.
[Français

More

Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License